Sclerosing polycystic adenoma (SPA) is a rare salivary gland neoplasm originally thought to represent a non-neoplastic lesion. Recently we have encountered an index case of apocrine intraductal carcinoma of parotid gland of 62-year-old man with invasive salivary duct carcinoma component arising from SPA, a combination of tumor entities that has never been published so far. Here, we further explore the nature of SPA by evaluating 36 cases that were identified from the authors' consultation files. The patients were 25 females and 11 males aged 11 to 79 years (mean, 47.8 y). All tumors originated from the parotid gland. Their size ranged from 11 to 70 mm (mean, 28 mm). Histologically, all cases revealed characteristic features of SPA, such as lobulated well-circumscribed growth, focal hyalinized sclerosis, presence of large acinar cells with abundant brightly eosinophilic intracytoplasmic granules, and ductal components with variable cytomorphologic characteristics, including foamy, vacuolated, apocrine, mucous, clear/ballooned, squamous, columnar and oncocyte-like cells. In all cases, there were foci of intraluminal solid and cribriform intercalated duct-like epithelial proliferations with variable dysplasia which were positive for S100 protein and SOX10, and fully enveloped by an intact layer of myoepithelial cells. In addition, 14/36 cases (39%) had focal intraductal cribriform and micropapillary apocrine-type dysplastic epithelial structures composed of cells positive for androgen receptors and negative for S100/SOX10. The intraductal proliferations of both types showed focal mild to severe dysplasia in 17 cases (17/36; 47%). Two cases showed overt malignant morphology ranging from high-grade intraductal carcinoma to invasive carcinoma with an apocrine ductal phenotype. Next generation sequencing using ArcherDX panel targeting RNA of 36 pan-cancer-related genes and/or a TruSight Oncology 170/500 Kit targeting a selection of DNA from 523 genes and RNA from 55 genes was performed. Tumor tissue was available for molecular analysis in 11 cases, and 9 (9/11; 82%) of them harbored genetic alterations in the PI3K pathway. Targeted sequencing revealed HRAS mutations c.37G>C, p.(Gly13Arg) (2 cases) and c.182A>G, p.(Gln61Arg) (2 cases), and PIK3CA mutations c.3140A>G, p.(His1047Arg) (3 cases), c.1633G>A, p.(Glu545Lys) (1 case), and c.1624G>A, p.(Glu542Lys) (1 case). Moreover, mutations in AKT1 c.49G>A, p.(Glu17Lys) and c.51dup, p.(Tyr18ValfsTer15); c.49_50delinsAG, p.(Glu17Arg) (as a double hit) were found (2 cases). In addition, germinal and somatic mutation of PTEN c.1003C>T, p.(Arg335Ter); c.445C>T, p.(Gln149Ter), respectively, were detected. Gene fusions were absent in all cases. These prevalent molecular alterations converging on one major cancer-related pathway support the notion that SPA is a true neoplasm with a significant potential to develop intraluminal epithelial proliferation with apocrine and/or intercalated duct-like phenotype. The name SPA more correctly reflects the true neoplastic nature of this enigmatic lesion.

• MeSH
• adenom enzymologie   genetika   patologie   MeSH
• dítě MeSH
• dospělí MeSH
• fenotyp MeSH
• fosfatidylinositol-3-kinasy třídy I genetika   MeSH
• fosfohydroláza PTEN genetika   MeSH
• genetická predispozice k nemoci MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mutace * MeSH
• nádorové biomarkery analýza   genetika   MeSH
• nádory cystické, mucinózní a serózní enzymologie   genetika   patologie   MeSH
• nádory příušní žlázy enzymologie   genetika   patologie   MeSH
• protoonkogenní proteiny c-akt genetika   MeSH
• protoonkogenní proteiny p21(ras) genetika   MeSH
• senioři MeSH
• skleróza MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH

Mucinous cystic neoplasm of the liver (MCN-L) and intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) are diagnoses that were classified by the World Health Organization in 2010 as mucin-producing bile duct tumors of the hepatobiliary system. The preoperative differential diagnosis between these two entities is difficult; the presence of a communication with the bile duct is usually considered as a typical sign of IPMN-B. However, the presence of an ovarian-like stroma (OLS) has been established to define the diagnosis of MCN-L. We present the case of a 33-year-old woman with a rapid progression of a cystic tumor of the liver. In 2 years, the lesion increased from 27 to 64 mm and a dilation of the left hepatic duct appeared. Percutaneous transhepatic drainage with a biopsy was performed. No malignant cells were found on biopsy. Because of the rapid progression of the cystic tumor and unclear malignant potential, left hemihepatectomy was performed. Even though tumor masses were present in the biliary duct, on the basis of the presence of OLS, histology finally confirmed MCN-L with intermediate-grade intraepithelial dysplasia to high-grade intraepithelial dysplasia. The patient is currently under oncologic follow-up with no signs of recurrence of the disease. We present a rare case where MCN-L caused a dilation of the left hepatic duct, a sign that is usually a characteristic of IPMN-B.

• MeSH
• biopsie MeSH
• cholangiografie MeSH
• diferenciální diagnóza MeSH
• dilatace patologická MeSH
• dospělí MeSH
• ductus hepaticus communis patologie   MeSH
• hepatektomie MeSH
• karcinom in situ komplikace   diagnóza   patologie   chirurgie   MeSH
• lidé MeSH
• magnetická rezonanční tomografie MeSH
• nádory cystické, mucinózní a serózní komplikace   diagnóza   patologie   chirurgie   MeSH
• nádory jater komplikace   diagnóza   patologie   chirurgie   MeSH
• nádory žlučových cest diagnóza   patologie   MeSH
• počítačová rentgenová tomografie MeSH
• prediktivní hodnota testů MeSH
• progrese nemoci MeSH
• tumor burden MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• přehledy MeSH

High grade serózní karcinomy (HGSC) jsou skupinou ovariálních, tubárních a peritoneálních nádorů vznikajících z prekurzorové léze převážně v distální části vejcovodu. V době zjištění diagnózy HGSC jsou ženy postiženy metastatickým šířením nádoru v dutině břišní s pětiletým přežíváním 10–30 %. Mezi ženami se zvýšeným rizikem HGSC (nejvíc s BRCA mutací), které podstoupily bilaterální adnexektomii, je 4–17 % těch, které mají STIC (serózní tubární intraepiteliální karcinom) nebo invazivní neoplazii, a přibližně 80 % těch neoplazií se nachází v ampulární části vejcovodu.

High-grade serous carcinomas (HGSC) are group of ovarial, tubal and peritoneal tumors arising from precursor lession most likelyfrom distal part of the fallopian tube. At the time of diagnosis of HGSC are women affected with metastatic sprej of the tumorinto abdominal cavity with 5 year survival of 10–30%. Among women with increased risk of HGSC (the most with BRCA mutation)witch underwent bilateral salpingo-oophorectomy is 4–17% diagnosed with STIC (serous tubal intraepithelial carcinoma) or withinvasive neoplasia a aproximately 80% those tumors are found in ampular part of the fallopian tube.

• MeSH
• geny BRCA1 MeSH
• geny BRCA2 MeSH
• komorbidita MeSH
• lidé MeSH
• mutace MeSH
• nádory cystické, mucinózní a serózní genetika   imunologie   patologie   MeSH
• nádory vaječníků genetika   imunologie   patologie   MeSH
• protein BRCA1 genetika   MeSH
• protein BRCA2 genetika   MeSH
• terciární prevence MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• práce podpořená grantem MeSH

INTRODUCTION: Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered: We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent follow-up procedure in women with an isolated STIC. Expert commentary: Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.

• MeSH
• adjuvantní chemoterapie metody   MeSH
• imunohistochemie MeSH
• incidence MeSH
• karcinom in situ diagnóza   patologie   terapie   MeSH
• lidé MeSH
• mutace MeSH
• nádory cystické, mucinózní a serózní diagnóza   patologie   terapie   MeSH
• nádory vejcovodů diagnóza   patologie   terapie   MeSH
• protein BRCA1 genetika   MeSH
• protein BRCA2 genetika   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

A unique renal neoplasm characterized by eosinophilic cytoplasm and solid and cystic growth was recently reported in patients with tuberous sclerosis complex (TSC). We searched multiple institutional archives and consult files in an attempt to identify a sporadic counterpart. We identified 16 morphologically identical cases, all in women, without clinical features of TSC. The median age was 57 years (range, 31 to 75 y). Macroscopically, tumors were tan and had a solid and macrocystic (12) or only solid appearance (4). Average tumor size was 50 mm (median, 38.5 mm; range, 15 to 135 mm). Microscopically, the tumors showed solid areas admixed with variably sized macrocysts and microcysts that were lined by cells with a pronounced hobnail arrangement. The cells had voluminous eosinophilic cytoplasm with prominent granular cytoplasmic stippling and round to oval nuclei with prominent nucleoli. Scattered histiocytes and lymphocytes were invariably present. Thirteen of 16 patients were stage pT1; 2 were pT2, and 1 was pT3a. The cells demonstrated a distinct immunoprofile: nuclear PAX8 expression, predominant CK20-positive/CK7-negative phenotype, patchy AMACR staining, but no CD117 reactivity. Thirteen of 14 patients with follow-up were alive and without disease progression after 2 to 138 months (mean: 53 mo; median: 37.5 mo); 1 patient died of other causes. Although similar to a subset of renal cell carcinomas (RCCs) seen in TSC, we propose that sporadic "eosinophilic, solid, and cystic RCC," which occurs predominantly in female individuals and is characterized by distinct morphologic features, predominant CK20-positive/CK7-negative immunophenotype, and indolent behavior, represents a novel subtype of RCC.

• MeSH
• analýza přežití MeSH
• časové faktory MeSH
• dospělí MeSH
• eozinofily chemie   patologie   MeSH
• imunohistochemie MeSH
• karcinom z renálních buněk chemie   genetika   mortalita   patologie   terapie   MeSH
• karyotypizace MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádorové biomarkery analýza   genetika   MeSH
• nádory cystické, mucinózní a serózní chemie   genetika   mortalita   patologie   terapie   MeSH
• nádory ledvin chemie   genetika   mortalita   patologie   terapie   MeSH
• prediktivní hodnota testů MeSH
• přežití po terapii bez příznaků nemoci MeSH
• progrese nemoci MeSH
• retrospektivní studie MeSH
• senioři MeSH
• srovnávací genomová hybridizace MeSH
• staging nádorů MeSH
• transmisní elektronová mikroskopie MeSH
• tumor burden MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Austrálie MeSH
• Evropa MeSH
• Severní Amerika MeSH

The authors report a case where undifferentiated (classic) penile intraepithelial neoplasia was associated with the presence of goblet cells throughout the full epithelial thickness and which later progressed into an invasive carcinoma. The lesion evolved in three consecutive biopsies from only surface epithelium occupying numerous goblet cells in the first to variably sized solid nodules in the dermis composed of atypical squamous and/or basaloid cells intermixed with numerous goblet cells in the third biopsy. Both cellular components expressed CK7 and p16 protein. Human Papillomavirus (HPV) genotyping revealed high risk HPV type 16. To the best of our knowledge, this is the first description of such a lesion occurring on the penis, which can be considered the penile analogue of cervical stratified mucin-producing intraepithelial lesion (SMILE). The correct diagnosis was rendered retrospectively, after recognition of the existence of a vulvar lesion resembling cervical SMILE. The initial biopsy was misinterpreted as extramammary Paget disease, which also constitutes the main pitfall in the differential diagnosis. Another important differential diagnosis is penile/vulvar mucinous metaplasia. The finding of atypical squamous epithelial cells positive for p16 associated with mucinous cells present throughout the full epithelial thickness is a clue to the diagnosis of penile SMILE.

• MeSH
• biopsie MeSH
• chybná diagnóza MeSH
• dysplazie děložního hrdla chemie   patologie   MeSH
• extramamární Pagetova nemoc patologie   MeSH
• imunohistochemie MeSH
• inhibitor p16 cyklin-dependentní kinasy analýza   MeSH
• invazivní růst nádoru MeSH
• karcinom in situ chemie   patologie   virologie   MeSH
• karcinom chemie   patologie   virologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lidský papilomavirus 16 izolace a purifikace   MeSH
• metaplazie MeSH
• nádorové biomarkery analýza   MeSH
• nádory cystické, mucinózní a serózní chemie   patologie   virologie   MeSH
• nádory děložního čípku chemie   patologie   MeSH
• nádory penisu chemie   patologie   virologie   MeSH
• pohárkové buňky chemie   patologie   virologie   MeSH
• prediktivní hodnota testů MeSH
• progrese nemoci MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• práce podpořená grantem MeSH

BACKGROUND: The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mutations. The aim of this study was to assess the efficacy and tolerability of olaparib in combination with chemotherapy, followed by olaparib maintenance monotherapy, versus chemotherapy alone in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer. METHODS: In this randomised, open-label, phase 2 study, adult patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to three previous courses of platinum-based chemotherapy and who were progression free for at least 6 months before randomisation received either olaparib (200 mg capsules twice daily, administered orally on days 1-10 of each 21-day cycle) plus paclitaxel (175 mg/m(2), administered intravenously on day 1) and carboplatin (area under the curve [AUC] 4 mg/mL per min, according to the Calvert formula, administered intravenously on day 1), then olaparib monotherapy (400 mg capsules twice daily, given continuously) until progression (the olaparib plus chemotherapy group), or paclitaxel (175 mg/m(2) on day 1) and carboplatin (AUC 6 mg/mL per min on day 1) then no further treatment (the chemotherapy alone group). Randomisation was done by an interactive voice response system, stratified by number of previous platinum-containing regimens received and time to disease progression after the previous platinum regimen. The primary endpoint was progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1, analysed by intention to treat. Prespecified exploratory analyses included efficacy by BRCA mutation status, assessed retrospectively. This study is registered with ClinicalTrials.gov, number NCT01081951, and has been completed. FINDINGS: Between Feb 12 and July 30, 2010, 173 patients at 43 investigational sites in 12 countries were enrolled into the study, of whom 162 were eligible and were randomly assigned to the two treatment groups (81 to the olaparib plus chemotherapy group and 81 to the chemotherapy alone group). Of these randomised patients, 156 were treated in the combination phase (81 in the olaparib plus chemotherapy group and 75 in the chemotherapy alone group) and 121 continued to the maintenance or no further treatment phase (66 in the olaparib plus chemotherapy group and 55 in the chemotherapy alone group). BRCA mutation status was known for 107 patients (either at baseline or determined retrospectively): 41 (38%) of 107 had a BRCA mutation (20 in the olaparib plus chemotherapy group and 21 in the chemotherapy alone group). Progression-free survival was significantly longer in the olaparib plus chemotherapy group (median 12.2 months [95% CI 9.7-15.0]) than in the chemotherapy alone group (median 9.6 months [95% CI 9.1-9.7) (HR 0.51 [95% CI 0.34-0.77]; p=0.0012), especially in patients with BRCA mutations (HR 0.21 [0.08-0.55]; p=0.0015). In the combination phase, adverse events that were reported at least 10% more frequently with olaparib plus chemotherapy than with chemotherapy alone were alopecia (60 [74%] of 81 vs 44 [59%] of 75), nausea (56 [69%] vs 43 [57%]), neutropenia (40 [49%] vs 29 [39%]), diarrhoea (34 [42%] vs 20 [27%]), headache (27 [33%] vs seven [9%]), peripheral neuropathy (25 [31%] vs 14 [19%]), and dyspepsia (21 [26%] vs 9 [12%]); most were of mild-to-moderate intensity. The most common grade 3 or higher adverse events during the combination phase were neutropenia (in 35 [43%] of 81 patients in the olaparib plus chemotherapy group vs 26 [35%] of 75 in the chemotherapy alone group) and anaemia (seven [9%] vs five [7%]). Serious adverse events were reported in 12 (15%) of 81 patients in the olaparib plus chemotherapy group and 16 of 75 (21%) patients in the chemotherapy alone group. INTERPRETATION: Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in BRCA-mutated patients, and had an acceptable and manageable tolerability profile. FUNDING: AstraZeneca.

• MeSH
• antitumorózní látky aplikace a dávkování   škodlivé účinky   MeSH
• aplikace orální MeSH
• časové faktory MeSH
• cílená molekulární terapie MeSH
• dospělí MeSH
• ftalaziny aplikace a dávkování   škodlivé účinky   MeSH
• inhibitory enzymů aplikace a dávkování   škodlivé účinky   MeSH
• intravenózní podání MeSH
• karboplatina aplikace a dávkování   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lokální recidiva nádoru * MeSH
• mladý dospělý MeSH
• mutace MeSH
• nádory cystické, mucinózní a serózní farmakoterapie   enzymologie   mortalita   patologie   MeSH
• nádory vaječníků farmakoterapie   enzymologie   genetika   mortalita   patologie   MeSH
• paclitaxel aplikace a dávkování   MeSH
• piperaziny aplikace a dávkování   škodlivé účinky   MeSH
• poly(ADP-ribosa)-polymerasy antagonisté a inhibitory   metabolismus   MeSH
• přežití po terapii bez příznaků nemoci MeSH
• protein BRCA1 genetika   MeSH
• protein BRCA2 genetika   MeSH
• protokoly antitumorózní kombinované chemoterapie škodlivé účinky   terapeutické užití   MeSH
• rozvrh dávkování léků MeSH
• senioři MeSH
• stupeň nádoru MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze II MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

• MeSH
• antitumorózní látky * aplikace a dávkování   škodlivé účinky   MeSH
• aplikace orální MeSH
• časové faktory MeSH
• cílená molekulární terapie MeSH
• dospělí MeSH
• ftalaziny * antagonisté a inhibitory   škodlivé účinky   MeSH
• inhibitory enzymů * aplikace a dávkování   škodlivé účinky   MeSH
• intravenózní podání MeSH
• karboplatina * aplikace a dávkování   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lokální recidiva nádoru MeSH
• mladý dospělý MeSH
• mutace MeSH
• nádory cystické, mucinózní a serózní * enzymologie   farmakoterapie   mortalita   patologie   MeSH
• nádory vaječníků * enzymologie   farmakoterapie   genetika   mortalita   patologie   MeSH
• paclitaxel * aplikace a dávkování   MeSH
• PARP inhibitory MeSH
• piperaziny * aplikace a dávkování   škodlivé účinky   MeSH
• poly(ADP-ribosa)-polymerasy * metabolismus   MeSH
• přežití po terapii bez příznaků nemoci MeSH
• protein BRCA1 * genetika   MeSH
• protein BRCA2 * genetika   MeSH
• protokoly antitumorózní kombinované chemoterapie * škodlivé účinky   terapeutické užití   MeSH
• randomizované kontrolované studie jako téma MeSH
• rozvrh dávkování léků MeSH
• senioři MeSH
• stupeň nádoru MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• senioři MeSH
• ženské pohlaví MeSH

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n=81; median (med), 11.53 μmol/l; range, 1.78-43.21 μmol/l) compared with controls with no ovarian pathology (n=27; med, 1.86 μmol/l; range, 0.94-9.73 μmol/l), and patients with benign ovarian tumor (n=51; med, 6.17 μmol/l; range, 1.12-25.23 μmol/l; P<0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.

• MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• lysofosfolipidy krev   MeSH
• nádorové biomarkery krev   MeSH
• nádory cystické, mucinózní a serózní krev   patologie   MeSH
• nádory vaječníků krev   patologie   MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• senzitivita a specificita MeSH
• staging nádorů MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Cystické nádory vycházející z ledvinného parenchymu jsou heterogenní skupinou jednotek s rozličnou histogenezou, biologickým chováním i prognózou. Ačkoliv agresivní multicystické tumory jsou extrémně vzácné, existují a urologové o nich musí vědět. Mezi typické zástupce multicystických tumorů je řazen multilokulární multicystický renální karcinom, smíšený epiteliální a stromální tumor ledviny a cystický nefrom. Jako cystické tumory lze uvést papilární renální karcinom a světlobuněčný karcinom, avšak tyto tumory jsou cysticky změněné sekundárně. Kavernózní hemangiom či lymfangiom jsou označovány jako multicystické.

Multicystic tumors originated from the kidney parenchyma form heterogenous group of tumors with different histogenesis, biological behavior and prognosis. However aggressive multicystic neoplasias are exceedingly rare, they occur and urologists should recognize that such a tumor could exist. Multilocular cystic clear cell renal cell carcinoma, mixed epithelial and stromal tumor of the kidney and cystic nephroma are considered to be typical examples of this group. Papillary renal cell carcinoma and clear renal cell carcinoma could be also considered as cystic tumors, but cystic change is always secondary. Also cavernous hemangioma and lymphangioma could be assigned as cystic or multicystic tumors.

• MeSH
• cystická onemocnění ledvin patologie   MeSH
• diferenciální diagnóza MeSH
• dospělí MeSH
• lidé MeSH
• nádory cystické, mucinózní a serózní patologie   ultrastruktura   MeSH
• nádory glandulární a epitelové patologie   ultrastruktura   MeSH
• nádory ledvin patologie   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• Publikační typ
• přehledy MeSH